By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting originating from Oklahoma City, Oklahoma, by NewsRx correspondents, research stated, "The last decade has witnessed enormous advances in the development and application of nanotechnology in cancer detection, diagnosis, and therapy culminating in the development of the nascent field of 'cancer nanomedicine.' A nanoparticle as per the National Institutes of Health (NIH) guidelines is any material that is used in the formulation of a drug resulting in a final product smaller than 1 micron in size. Nanoparticle-based therapeutic systems have gained immense popularity due to their ability to overcome biological barriers, effectively deliver hydrophobic therapies, and preferentially target disease sites."
Our news editors obtained a quote from the research from the University of Oklahoma, "Currently, many formulations of nanocarriers are utilized including lipid-based, polymeric and branched polymeric, metal-based, magnetic, and mesoporous silica. Innovative strategies have been employed to exploit the multicomponent, three-dimensional constructs imparting multifunctional capabilities. Engineering such designs allows simultaneous drug delivery of chemotherapeutics and anticancer gene therapies to site-specific targets. In lung cancer, nanoparticle-based therapeutics is paving the way in the diagnosis, imaging, screening, and treatment of primary and metastatic tumors. However, translating such advances from the bench to the bedside has been severely hampered by challenges encountered in the areas of pharmacology, toxicology, immunology, large-scale manufacturing, and regulatory issues."
According to the news editors, the research concluded: "This review summarizes current progress and challenges in nanoparticle-based drug delivery systems, citing recent examples targeted at lung cancer treatment."
For more information on this research see: Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges. Journal of Nanomaterials, 2013;():1-11. Journal of Nanomaterials can be contacted at: Hindawi Publishing Corporation, 410 Park Avenue, 15TH Floor, #287 Pmb, New York, NY 10022, USA. (Hindawi Publishing - www.hindawi.com; Journal of Nanomaterials - www.hindawi.com/journals/jnm/)
The news editors report that additional information may be obtained by contacting A. Babu, University of Oklahoma, Hlth Sci Center, Grad Program Biomed Sci, Oklahoma City, OK 73104, United States. Additional authors for this research include A.K. Templeton, A. Munshi and R. Ramesh (see also Biotechnology).
Keywords for this news article include: Biotechnology, Oncology, Treatment, Oklahoma City, United States, Cancer Gene Therapy, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC